Tepezza receives marketing authorisation from MHRA

News
Article

Teprotumumab is the first therapy specifically licensed for the treatment of moderate-to-severe thyroid eye disease in the UK

Viersen, Germany - December 1. 2021: Closeup of mobile phone screen with logo lettering of UK MHRA agency, serum vials and syringe background (Image credit: ©Ralf/Adobe Stock)

(Image credit: ©Ralf/Adobe Stock)

Tepezza (teprotumumab) received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as the first therapy specifically licensed for the treatment of adult patients with moderate-to-severe thyroid eye disease (TED), announced Amgen.1

“The marketing authorisation for teprotumumab as the first therapy specifically licensed for thyroid eye disease (TED) in the UK marks a step forward for the patient community,” said Dr Tony Patrikios, Executive Medical Director, Amgen UK & Ireland.

The marketing authorisation for teprotumumab is supported by multiple clinical studies – OPTIC phase 3 clinical trial, TED01RV phase 2 clinical study, HZNP-TEP-403 phase 4 clinical study, and the OPTIC-J phase 3 study.1

OPTIC was a prospective, multi-centre randomized, doubled-blind, placebo-controlled phase 3 trial of the IGF-1R inhibitor teprotumumab or placebo in adults with Graves’ disease and active moderate-to-severe thyroid eye disease. It enrolled 83 patients between the ages of 18-80 years old and randomized 1:1 to receive 8 intravenous infusions of either teprotumumab or placebo.

The study demonstrated teprotumumab significantly improved the primary endpoint, proptosis (eye bulging) responder rate. The study showed that at 24 weeks, 83% of participants demonstrated a reduction of at least 2mm compared to baseline, compared to 10% of patients treated with placebo.1

“TED can negatively affect patients’ lives impacting vision, causing eye pain, making everyday tasks difficult and causing a loss of self-confidence,” Dr Patrikios said. “This authorisation introduces a new alternative treatment option and reinforces Amgen’s commitment to supporting eligible patients with serious, underserved conditions.”

This progressive and potentially vision-threatening condition, approximately 50,000 people are living with TED in the UK. TED can cause eye bulging, double vision, eye pain, redness, and swelling.

“For adult patients living with thyroid eye disease, it can be challenging to receive a diagnosis and referral to specialist centers,” said Dr Jimmy Uddin, Consultant Ophthalmologist, Oculoplastic & Orbital Surgeon, Moorfields Eye Hospital and St George’s Hospital Medical School. “Teprotumumab offers eligible TED patients in the UK an important new treatment option.”

Reference:
1. Amgen’s TEPEZZA (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom. BioSpace. Published May 8, 2025. Accessed May 8, 2025. https://www.biospace.com/press-releases/amgens-tepezza-teprotumumab-granted-marketing-authorisation-as-the-first-targeted-treatment-specifically-for-adults-with-moderate-to-severe-thyroid-eye-disease-ted-in-the-united-kingdom

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.